Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jaci.2020.10.040 http://scihub22266oqcxt.onion/10.1016/j.jaci.2020.10.040 33221383!7677074!33221383     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Allergy+Clin+Immunol 2021 ; 147 (2): 545-557.e9 Nephropedia Template TP {{tp|p=33221383|t=2021. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19 |pdf=|usr=}}{{33221383}} gab.com Text Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19 JO: J Allergy Clin Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33221383 #FOAvip BACKGROUND: Whereas severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody tests are increasingly being used to estimate the prevalence of SARS-CoV-2 infection, the determinants of these antibody responses remain unclear. OBJECTIVES: Our aim was to evaluate systemic and mucosal antibody responses toward SARS-CoV-2 in mild versus severe coronavirus disease 2019 (COVID-19) cases. METHODS: Using immunoassays specific for SARS-CoV-2 spike proteins, we determined SARS-CoV-2-specific IgA and IgG in sera and mucosal fluids of 2 cohorts, including SARS-CoV-2 PCR-positive patients (n = 64) and PCR-positive and PCR-negtive health care workers (n = 109). RESULTS: SARS-CoV-2-specific serum IgA titers in patients with mild COVID-19 were often transiently positive, whereas serum IgG titers remained negative or became positive 12 to 14 days after symptom onset. Conversely, patients with severe COVID-19 showed a highly significant increase of SARS-CoV-2-specific serum IgA and IgG titers after symptom onset. Very high titers of SARS-CoV-2-specific serum IgA were correlated with severe acute respiratory distress syndrome. Interestingly, some health care workers with negative SARS-CoV-2-specific serum antibody titers showed SARS-CoV-2-specific IgA in mucosal fluids with virus-neutralizing capacity in some cases. SARS-CoV-2-specific IgA titers in nasal fluids were inversely correlated with age. CONCLUSIONS: Systemic antibody production against SARS-CoV-2 develops mainly in patients with severe COVID-19, with very high IgA titers seen in patients with severe acute respiratory distress syndrome, whereas mild disease may be associated with transient production of SARS-CoV-2-specific antibodies but may stimulate mucosal SARS-CoV-2-specific IgA secretion. Twit Text FOAVip Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19 ????J Allergy Clin Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33221383 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33221383 #FOAvip English Wikipedia <ref>{{Cite pmid|33221383}}</ref> Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19 #MMPMID33221383 Cervia C; Nilsson J; Zurbuchen Y; Valaperti A; Schreiner J; Wolfensberger A; Raeber ME; Adamo S; Weigang S; Emmenegger M; Hasler S; Bosshard PP; De Cecco E; Bachli E; Rudiger A; Stussi-Helbling M; Huber LC; Zinkernagel AS; Schaer DJ; Aguzzi A; Kochs G; Held U; Probst-Muller E; Rampini SK; Boyman O J Allergy Clin Immunol 2021[Feb]; 147 (2): 545-557.e9 PMID33221383show ga BACKGROUND: Whereas severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody tests are increasingly being used to estimate the prevalence of SARS-CoV-2 infection, the determinants of these antibody responses remain unclear. OBJECTIVES: Our aim was to evaluate systemic and mucosal antibody responses toward SARS-CoV-2 in mild versus severe coronavirus disease 2019 (COVID-19) cases. METHODS: Using immunoassays specific for SARS-CoV-2 spike proteins, we determined SARS-CoV-2-specific IgA and IgG in sera and mucosal fluids of 2 cohorts, including SARS-CoV-2 PCR-positive patients (n = 64) and PCR-positive and PCR-negtive health care workers (n = 109). RESULTS: SARS-CoV-2-specific serum IgA titers in patients with mild COVID-19 were often transiently positive, whereas serum IgG titers remained negative or became positive 12 to 14 days after symptom onset. Conversely, patients with severe COVID-19 showed a highly significant increase of SARS-CoV-2-specific serum IgA and IgG titers after symptom onset. Very high titers of SARS-CoV-2-specific serum IgA were correlated with severe acute respiratory distress syndrome. Interestingly, some health care workers with negative SARS-CoV-2-specific serum antibody titers showed SARS-CoV-2-specific IgA in mucosal fluids with virus-neutralizing capacity in some cases. SARS-CoV-2-specific IgA titers in nasal fluids were inversely correlated with age. CONCLUSIONS: Systemic antibody production against SARS-CoV-2 develops mainly in patients with severe COVID-19, with very high IgA titers seen in patients with severe acute respiratory distress syndrome, whereas mild disease may be associated with transient production of SARS-CoV-2-specific antibodies but may stimulate mucosal SARS-CoV-2-specific IgA secretion. |Adult[MESH] |Aged[MESH] |Antibodies, Viral/blood/*immunology[MESH] |COVID-19/blood/*immunology[MESH] |Female[MESH] |Humans[MESH] |Immunoglobulin A/blood/immunology[MESH] |Immunoglobulin G/blood/immunology[MESH] |Male[MESH] |Middle Aged[MESH] |Mucous Membrane/*immunology[MESH] |SARS-CoV-2/*immunology[MESH] |Saliva/immunology[MESH] |Severity of Illness Index[MESH]Systemic and mucosal antibody responses specific to SARS-CoV-2 during (epmc).pdf DeepDyve Pubget Overpricing